David Hakimian – Trademark Portfolio
Entity Type: 01
David Hakimian owns a portfolio of 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as E B, EARTHBAR, and EARTH BAR. Of these, 4 are registered. The portfolio spans 5 Nice Classification classes, led by Class 43 (Hotels & Restaurants) and Class 44 (Medical Services). Headquartered in West Hollywood, CA.
8155 Santa Monica Cl.
West Hollywood, CA 90046
Showing of trademarks Trademarks
Trademark Classifications
David Hakimian's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does David Hakimian have?
David Hakimian has 14 U.S. trademarks filed with the USPTO. Of these, 4 registered, 5 abandoned, 5 cancelled.
What trademark classes does David Hakimian file in?
David Hakimian files trademarks across 5 Nice Classification classes. The most active classes are Class 43 (Hotels & Restaurants), Class 44 (Medical Services), Class 35 (Advertising & Business), Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment). Class 43 covers services for providing food and drink; temporary accommodation.
What are David Hakimian's most well-known trademarks?
David Hakimian's registered trademark portfolio includes well-known marks such as E B, EARTHBAR, and EARTH BAR. These are among 4 currently registered trademarks in the portfolio.
What is David Hakimian's trademark registration success rate?
David Hakimian has a 29% trademark registration rate, with 4 out of 14 resolved applications resulting in successful registration. Currently, 0 applications are pending review.